The present disclosure includes a monoclonal antibody or antibody fragment that binds to an epitope consisting of 5 to 20 consecutive amino acids in the amino acid sequence of SEQ ID NO: 1, and a method of detecting or quantifying an Ripr-derived malaria vaccine antigen comprising contacting a sample with the monoclonal antibody or antibody fragment.

The invention provides compositions and methods for preventing or reducing the severity of malaria.

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to Plasmodium falciparum reticulocyte binding protein homologue 5 (PfRH5), compositions thereof and methods of making such antibodies, fragments and compositions. Method and compositions for treating, preventing or diagnosing Plasmodium falciparum infection and malaria are also part of the present invention.

The present disclosure provides immunogenic compositions and methods for vaccination with a CelTOS immunogen. The immunogenic composition comprises Babesia, Theileria or Cytauxzoon CelTOS. The immunogenic composition may also comprise CelTOS with structural changes that affect immune recognition.

The invention pertains to methods and vaccines suitable for preventing or reducing malaria transmission. The vaccines block the interaction between α-tubulin from a malarial parasite and FREP-1 from the mid-gut of a malaria carrier mosquito, for example, Anopheles gambiae.

The invention describes a method of generating antibodies to a mixture of peptidogenic proteins wherein the peptidogenic protein has altered conformational dynamics as compared to a starting protein and wherein the peptidogenic protein has a similar conformation to the starting protein. The peptidogenic proteins can be used to induce an immune response, which can lead to the generation of antibodies and/or can be used to vaccinate a mammal.

An automated system that can be used for prosthetic heart valve manufacturing or suturing procedures. The system can include a first automated fixture that includes an articulating arm and a target device holder. The system can also include one or more additional automated fixtures, which can be configured as one or more suturing arms that include another articulating arm and a needle holder. The first automated fixture can be configured to rotate a target device held by the holder to allow the one or more additional automated fixtures to perform operations such as form sutures on the target device without intervention of a human operator. The system can include a targeting system configured to provide positioning feedback to the system.

The present invention relates to a polypeptide consisting of an amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, (b) an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8 by substitution, deletion, addition, or insertion of 1 to 10, preferably 1-5, more preferably 1, 2 or 3 amino acids, and (c) an amino acid sequence that has at least 95%, preferably 97%, more preferably 99% sequence identity with the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, and a malaria vaccine comprising the polypeptide, for example.

An automated system that can be used for prosthetic heart valve manufacturing or suturing procedures. The system can include a first automated fixture that includes an articulating arm and a target device holder. The system can also include one or more additional automated fixtures, which can be configured as one or more suturing arms that include another articulating arm and a needle holder. The first automated fixture can be configured to rotate a target device held by the holder to allow the one or more additional automated fixtures to perform operations such as form sutures on the target device without intervention of a human operator. The system can include a targeting system configured to provide positioning feedback to the system.

A system, method, apparatus and diagnostic test for Plasmodium vivax, to determine a likelihood of a specific timing of infection by P. vivax in a subject, and hence identify individuals with a high probability of being infected with otherwise undetectable liver-stage hypnozoites. The system, method, apparatus and diagnostic test relate to the identification of hypnozoites (“dormant” liver-stages), or at least of the likelihood of the subject being so infected. Optionally and preferably, the specific timing relates to recent infections, for example within the last 9 months.